On the move again, page-3

Yes pretty darn boring! But that said all good things take time and we are talking about a nuclear device here! All reports show no leaching or ill effects. Resection data is terrific. This will get approval this year and there will likely be a buying frenzy as instos pile in. Under owned by them and they now recognise the potential value via SRX bidding war. OSL's device is first line and into both liver and pancreas. Unfortunately instos invest OPM and hence want total de-risking or CE Mark. Should be a nice re-rating pre Xmas. A nice Xmas present for all (or happy holidays present).